Sanofi SA (EPA:SAN) has been given a €76.00 ($82.61) price objective by analysts at Jefferies Group in a report issued on Thursday, MarketBeat Ratings reports. The brokerage currently has a a “neutral” rating on the stock.

Sanofi SA (EPA:SAN) opened at 76.20 on Thursday. The company has a market capitalization of €99.53 billion and a price-to-earnings ratio of 19.06. Sanofi SA has a 12-month low of €70.94 and a 12-month high of €101.10. The stock has a 50 day moving average price of €0.00 and a 200-day moving average price of €0.00.

Other equities analysts have also recently issued reports about the company. Morgan Stanley set a €93.00 ($101.09) price objective on Sanofi SA and gave the company a “neutral” rating in a research report on Tuesday, October 13th. Sanford C. Bernstein set a €98.00 ($106.52) price objective on Sanofi SA and gave the company a “buy” rating in a research report on Wednesday, October 21st. Goldman Sachs set a €81.00 ($88.04) price objective on Sanofi SA and gave the company a “neutral” rating in a research report on Wednesday, October 28th. JPMorgan Chase & Co. set a €87.00 ($94.57) price objective on Sanofi SA and gave the company a “sell” rating in a research report on Wednesday, October 28th. Finally, Citigroup Inc. set a €99.00 ($107.61) price objective on Sanofi SA and gave the company a “neutral” rating in a research report on Thursday, October 29th. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and five have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of €91.25 ($99.18).

Sanofi is a healthcare company focused on patient needs and engaged in the research, development, manufacture and marketing of healthcare products. The Company is organized around three principal activities: Pharmaceuticals, Human Vaccines via Sanofi Pasteur, and Animal Health via Merial. The Company invests in emerging markets, diabetes solutions, vaccines, consumer health care, animal health, genzyme and other products. The emerging markets platform includes products from all three of the Company’s principal activities. Under the Company’s Pharmaceuticals business, products are grouped into the key fields of diabetes solutions, rare diseases, multiple sclerosis, oncology, thrombosis and cardiovascular disease prevention, nephrology and bio-surgery. The Human Vaccines activity is operated through Sanofi Pasteur. The Animal Health activity is carried out through Merial.

Receive News & Ratings for Sanofi SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi SA and related companies with MarketBeat.com's FREE daily email newsletter.